Published Oct. 6, 2026. The Food and Drug Administration is seeking public input on how early-stage clinical trials of ibogaine should be designed and monitored as federal agencies prepare government-funded studies for opioid addiction and post-traumatic stress disorder.
The FDA announced the request on Oct. 5. Reuters reported the same day that comments are due Nov. 20, 2026.
Questions the FDA wants researchers to address
The agency is asking for evidence and recommendations on dose selection and escalation, patient eligibility, the appropriate care setting, safety monitoring, study-stopping rules and independent oversight.
Those questions are especially important because ibogaine has been associated with dangerous heart-rhythm problems and possible neurological toxicity. Cardiac screening, continuous monitoring and clear stopping criteria are expected to be central to any responsible trial design.
What the federal research will study
The Department of Health and Human Services is supporting early-stage research through the Advanced Research Projects Agency for Health and the National Institute on Drug Abuse. The planned work is intended to evaluate safety and gather evidence, not to authorize routine clinical use.
Ibogaine is a psychoactive compound derived from the iboga plant. It remains a Schedule I controlled substance in the United States and is not FDA-approved to treat opioid-use disorder, PTSD or any other condition.
What this announcement does not mean
The request for information is not an approval, a recommendation for patients or proof that ibogaine is effective. Early-phase trials are designed primarily to establish safety, dosing and whether larger studies are justified.
People seeking treatment for opioid-use disorder or PTSD should use established medical care and should not treat an upcoming research program as a substitute for approved therapy.
Follow Health News and Science News for evidence-based medical and research updates.
Featured image: Photo by Louis Reed on Unsplash. Image is illustrative.